Literature DB >> 35260846

Modelling amyotrophic lateral sclerosis in rodents.

Tiffany W Todd1, Leonard Petrucelli2.   

Abstract

The efficient study of human disease requires the proper tools, one of the most crucial of which is an accurate animal model that faithfully recapitulates the human condition. The study of amyotrophic lateral sclerosis (ALS) is no exception. Although the majority of ALS cases are considered sporadic, most animal models of this disease rely on genetic mutations identified in familial cases. Over the past decade, the number of genes associated with ALS has risen dramatically and, with each new genetic variant, there is a drive to develop associated animal models. Rodent models are of particular importance as they allow for the study of ALS in the context of a living mammal with a comparable CNS. Such models not only help to verify the pathogenicity of novel mutations but also provide critical insight into disease mechanisms and are crucial for the testing of new therapeutics. In this Review, we aim to summarize the full spectrum of ALS rodent models developed to date.
© 2022. Springer Nature Limited.

Entities:  

Mesh:

Year:  2022        PMID: 35260846     DOI: 10.1038/s41583-022-00564-x

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  375 in total

1.  ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

Authors:  L I Bruijn; M W Becher; M K Lee; K L Anderson; N A Jenkins; N G Copeland; S S Sisodia; J D Rothstein; D R Borchelt; D L Price; D W Cleveland
Journal:  Neuron       Date:  1997-02       Impact factor: 17.173

Review 2.  Genetic Convergence Brings Clarity to the Enigmatic Red Line in ALS.

Authors:  Casey Cook; Leonard Petrucelli
Journal:  Neuron       Date:  2019-03-20       Impact factor: 17.173

3.  Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1.

Authors:  P Andreas Jonsson; Karin S Graffmo; Thomas Brännström; Peter Nilsson; Peter M Andersen; Stefan L Marklund
Journal:  J Neuropathol Exp Neurol       Date:  2006-12       Impact factor: 3.685

4.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria.

Authors:  P C Wong; C A Pardo; D R Borchelt; M K Lee; N G Copeland; N A Jenkins; S S Sisodia; D W Cleveland; D L Price
Journal:  Neuron       Date:  1995-06       Impact factor: 17.173

5.  Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis.

Authors:  M E Gurney; T J Fleck; C S Himes; E D Hall
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

6.  Neuroprotective effect of oxidized galectin-1 in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Ren Chang-Hong; Manabu Wada; Shingo Koyama; Hideki Kimura; Shigeki Arawaka; Toru Kawanami; Keiji Kurita; Toshihiko Kadoya; Masashi Aoki; Yasuto Itoyama; Takeo Kato
Journal:  Exp Neurol       Date:  2005-07       Impact factor: 5.330

7.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

Authors:  M E Gurney; H Pu; A Y Chiu; M C Dal Canto; C Y Polchow; D D Alexander; J Caliendo; A Hentati; Y W Kwon; H X Deng
Journal:  Science       Date:  1994-06-17       Impact factor: 47.728

8.  Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis.

Authors:  M E Ripps; G W Huntley; P R Hof; J H Morrison; J W Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.

Authors:  D R Rosen; T Siddique; D Patterson; D A Figlewicz; P Sapp; A Hentati; D Donaldson; J Goto; J P O'Regan; H X Deng
Journal:  Nature       Date:  1993-03-04       Impact factor: 49.962

10.  Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice.

Authors:  Hidefumi Ito; Reika Wate; Jianhua Zhang; Shizuo Ohnishi; Satoshi Kaneko; Hisashi Ito; Satoshi Nakano; Hirofumi Kusaka
Journal:  Exp Neurol       Date:  2008-07-31       Impact factor: 5.330

View more
  2 in total

1.  Early and progressive dysfunction revealed by in vivo neurite imaging in the rNLS8 TDP-43 mouse model of ALS.

Authors:  Akram Zamani; Adam K Walker; Ben Rollo; Katie L Ayers; Raysha Farah; Terence J O'Brien; David K Wright
Journal:  Neuroimage Clin       Date:  2022-04-22       Impact factor: 4.891

Review 2.  Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?

Authors:  Hugo Alarcan; Yara Al Ojaimi; Debora Lanznaster; Jean-Michel Escoffre; Philippe Corcia; Patrick Vourc'h; Christian R Andres; Charlotte Veyrat-Durebex; Hélène Blasco
Journal:  J Pers Med       Date:  2022-06-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.